LENZ Therapeutics
LENZ
65 hedge funds and large institutions have $95.4M invested in LENZ Therapeutics in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 20 increasing their positions, 15 reducing their positions, and 9 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
33% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 15
17% more call options, than puts
Call options by funds: $446K | Put options by funds: $382K
3% more funds holding
Funds holding: 63 → 65 (+2)
2% more capital invested
Capital invested by funds: $93.9M → $95.4M (+$1.55M)
0.21% less ownership
Funds ownership: 7.27% → 7.06% (-0.21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$13.7M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$1.85M |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$371K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$273K |
| 5 |
Man Group
London,
United Kingdom
|
+$240K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.4M |
| 2 |
O
OrbiMed
New York
|
-$2.69M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.83M |
| 4 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$807K |
| 5 |
Goldman Sachs
New York
|
-$739K |
LENZ Hedge Fund Activity: Q4 2022 in Review
65 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q4 2022, worth a combined $95.4M — up 1.7% from $93.9M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new LENZ positions and 9 closed out — a net gain of 4 holders — while 20 added to existing stakes and 15 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $13.7M. The largest seller was Fidelity Investments, cutting an estimated $12.4M.
- 65 institutional investors held LENZ Therapeutics (LENZ) as of Q4 2022, up from 63 in Q3 2022.
- Funds reported $95.4M of LENZ Therapeutics stock for Q4 2022, up 1.7% quarter-over-quarter.
- 13 funds opened new LENZ Therapeutics positions in Q4 2022 and 9 closed out, a net change of +4 holders.
- The largest LENZ Therapeutics buyer in Q4 2022 was EcoR1 Capital, an estimated $13.7M added.
- The largest LENZ Therapeutics seller in Q4 2022 was Fidelity Investments, an estimated $12.4M sold.
Based on aggregated 13F filings for Q4 2022.